A 78-kDa glucose-regulated protein is involved in the decrease of interleukin-6 secretion by lead treatment from astrocytes

American Journal of Physiology - Cell Physiology

Volumn 293, Issue 3, 2007, Pages

  Qian, Yongchang ^a   Zheng, Ying ^a   Weber, Deanna ^a   Tiffany Castiglioni, Evelyn ^a  

^a TEXAS A AND M UNIVERSITY   (United States)

Author keywords

Chaperone; Cytokine; Protein protein interactions

Indexed keywords

CHAPERONE; COMPLEMENTARY DNA; ENHANCED GREEN FLUORESCENT PROTEIN; GLUCOSE REGULATED PROTEIN 78; INTERLEUKIN 6; LEAD;

ANIMAL CELL; ARTICLE; ASTROCYTE; CHIMERA; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; MOLECULAR CLONING; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; RAT;

ANIMALS; ASTROCYTES; CELLS, CULTURED; GREEN FLUORESCENT PROTEINS; HEAT-SHOCK PROTEINS; INTERLEUKIN-6; LEAD; LUMINESCENT PROTEINS; MOLECULAR CHAPERONES; NEUROTOXINS; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT FUSION PROTEINS; TRANSFECTION;

RATTUS;

EID: 34548774083     PISSN: 03636143     EISSN: 15221563     Source Type: Journal    
DOI: 10.1152/ajpcell.00059.2007     Document Type: Article

References (41)

1. Anttila A, Heikkila P, Nykyri E, Kauppinen T, Pukkala E, Hernberg S, Hemminki K. Risk of nervous system cancer among workers exposed to lead. J Occup Environ Med 38: 131-136, 1996.
2. Balschun D, Wetzel W, Del Rey A, Pitossi F, Schneider H, Zuschratter W, Besedovsky HO. Interleukin-6: a cytokine to forget. FASEB J 18: 1788-1790, 2004.
3. Bissonnette CJ, Klegeris A, McGeer PL, McGeer EG. Interleukin 1alpha and interleukin 6 protect human neuronal SH-SY5Y cells from oxidative damage. Neurosci Lett 361: 40-43, 2004.
4. Bolin LM, Strycharska-Orczyk I, Murray R, Langston JW, Di Monte D. Increased vulnerability of dopaminergic neurons in MPTP-lesioned interleukin-6 deficient mice. J Neurochem 83: 167-175, 2002.
5. Bradbury MW, Deane R. Permeability of the blood-brain barrier to lead. Neurotoxicology 14: 131-136, 1993.
6. Cocco P, Dosemeci M, Heineman EF. Brain cancer and occupational exposure to lead. J Occup Environ Med 40: 937-942, 1998.
7. Dietzel S, Eils R, Satzler K, Bornfleth H, Jauch A, Cremer C, Cremer T. Evidence against a looped structure of the inactive human X-chromosome territory. Exp Cell Res 240: 187-196, 1998.
8. Duckett S, Galle P, Kradin R. The relationship between Parkinson syndrome and vascular siderosis: an electron microprobe study. Ann Neurol 2: 225-229, 1977.
9. Gorell JM, Johnson CC, Rybicki BA, Peterson EL, Kortsha GX, Brown GG, Richardson RJ. Occupational exposure to manganese, copper, lead, iron, mercury and zinc and the risk of Parkinson's disease. Neurotoxicology 20: 239-247, 1999.
10. Gruol DL, Nelson TE. Physiological and pathological roles of interleukin-6 in the central nervous system. Mol Neurobiol 15: 307-339, 1997.
11. Hendershot LM, Ting J, Lee AS. Identity of the immunoglobulin heavy-chain-binding protein with the 78,000-dalton glucose-regulated protein and the role of posttranslational modifications in its binding function. Mol Cell Biol 8: 4250-4256, 1988.
12. Holtzman D, DeVries C, Nguyen H, Olson J, Bensch K. Maturation of resistance to lead encephalopathy: cellular and subcellular mechanisms. Neurotoxicology 5: 97-124, 1984.
13. Hori O, Matsumoto M, Kuwabara K, Maeda Y, Ueda H, Ohtsuki T, Kinoshita T, Ogawa S, Stern DM, Kamada T. Exposure of astrocytes to hypoxia/reoxygenation enhances expression of glucose-regulated protein 78 facilitating astrocyte release of the neuroprotective cytokine interleukin 6. J Neurochem 66: 973-979, 1996.
14. Iwakoshi NN, Lee AH, Vallabhajosyula P, Otipoby KL, Rajewsky K, Glimcher LH. Plasma cell differentiation and the unfolded protein response intersect at the transcription factor XBP-1. Nat Immun 4: 321-329, 2003.
15. Jares-Erijman EA, Jovin TM. FRET imaging. Nat Biotechnol 21: 1387-1395, 2003.
16. Kishikawa H, Lawrence DA. Differential production of interleukin-6 in the brain and spleen of mice treated with lipopolysaccharide in the presence and absence of lead. J Toxicol Environ Health A 53: 357-373, 1998.
17. Kuhn W, Winkel R, Woitalla D, Meves S, Przuntek H, Muller T. High prevalence of Parkinsonism after occupational exposure to lead-sulfate batteries. Neurology 50: 1885-1886, 1998.
18. Lindahl LS, Bird L, Legare ME, Mikeska G, Bratton GR, Tiffany-Castiglioni E. Differential ability of astroglia and neuronal cells to accumulate lead: dependence on cell type and on degree of differentiation. Toxicol Sci 50: 236-243, 1999.
19. Loddick SA, Turnbull AV, Rothwell NJ. Cerebral interleukin-6 is neuroprotective during permanent focal cerebral ischemia in the rat. J Cereb Blood Flow Metab 18: 176-179, 1998.
20. Luo S, Mao C, Lee B, Lee AS. GRP78/BiP is required for cell proliferation and protecting the inner cell mass from apoptosis during early mouse embryonic development. Mol Cell Biol 26: 5688-5697, 2006.
21. Mann DL. Stress-activated cytokines and the heart: from adaptation to maladaptation. Annu Rev Physiol 65: 81-101, 2003.
22. Markowitz M. Lead poisoning: a disease for the next millennium. Curr Probl Pediatr 30: 62-70, 2000.
23. Melnick J, Dul JL, Argon Y. Sequential interaction of the chaperones BiP and GRP94 with immunoglobulin chains in the endoplasmic reticulum. Nature 370: 373-375, 1994.
24. Munro S, Pelham HR. A C-terminal signal prevents secretion of luminal ER proteins. Cell 48: 899-907, 1987.
25. Needleman HL, Riess JA, Tobin MJ, Biesecker GE, Greenhouse JB. Bone lead levels and delinquent behavior. JAMA 275: 363-369, 1996.
26. Pavelko KD, Howe CL, Drescher KM, Gamez JD, Johnson AJ, Wei T, Ransohoff RM, Rodriguez M. Interleukin-6 protects anterior horn neurons from lethal virus-induced injury. J Neurosci 23: 481-492, 2003.
27. Penkowa M, Camats J, Hadberg H, Quintana A, Rojas S, Giralt M, Molinero A, Campbell IL, Hidalgo J. Astrocyte-targeted expression of interleukin-6 protects the central nervous system during neuroglial degeneration induced by 6-aminonicotinamide. J Neurosci Res 73: 481-496, 2003.
28. Pizzi M, Sarnico I, Boroni F, Benarese M, Dreano M, Garotta G, Valerio A, Spano P. Prevention of neuron and oligodendrocyte degeneration by interleukin-6 (IL-6) and IL-6 receptor/IL-6 fusion protein in organotypic hippocampal slices. Mol Cell Neurosci 25: 301-311, 2004.
29. Qian Y, Harris ED, Zheng Y, Tiffany-Castiglioni E. Lead targets GRP78, a molecular chaperone, in C6 rat glioma cells. Toxicol Appl Pharmacol 163: 260-266, 2000.
30. Qian Y, Mikeska G, Harris ED, Bratton GR, Tiffany-Castiglioni E. Effect of lead exposure and accumulation on copper homeostasis in cultured C6 rat glioma cells. Toxicol Appl Pharmacol 158: 41-49, 1999.
31. Qian Y, Tiffany-Castiglioni E. Lead-induced endoplasmic reticulum (ER) stress responses in the nervous system. Neurochem Res 28: 153-162, 2003.
32. Qian Y, Zheng Y, Ramos KS, Tiffany-Castiglioni E. GRP78 compartmentalized redistribution in Pb-treated glia: role of GRP78 in lead-induced oxidative stress. Neurotoxicology 26: 267-275, 2005.
33. Selevan SG, Rice DC, Hogan KA, Euling SY, Pfahles-Hutchens A, Bethel J. Blood lead concentration and delayed puberty in girls. N Engl J Med 348: 1527-1536, 2003.
34. Sterneck E, Kaplan DR, Johnson PF. Interleukin-6 induces expression of peripherin and cooperates with Trk receptor signaling to promote neuronal differentiation in PC12 cells. J Neurochem 67: 1365-1374, 1996.
35. Stiles KM, Bellinger DC. Neuropsychological correlates of low-level lead exposure in school-age children: a prospective study. Neurotoxicol Teratol 15: 27-35, 1993.
36. Taga T, Kishimoto T. Gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol 15: 797-819, 1997.
37. Tiffany-Castiglioni E, Qian Y. Astroglia and lead neurotoxicity. In: The Role of Glia in Neurotoxicity (2nd ed.), edited by Aschner M, Costa LG. Boca Raton, FL: CRC, 2005, chapt. 26, p. 417-437.
38. Tiffany-Castiglioni E, Sierra EM, Wu JN, Rowles TK. Lead toxicity in neuroglia. Neurotoxicology 10: 417-443, 1989.
39. Tiffany-Castiglioni E, Zmudzki J, Wu JN, Bratton GR. Effects of lead treatment on intracellular iron and copper concentrations in cultured astroglia. Metab Brain Dis 2: 61-79, 1987.
40. Tong S, Baghurst PA, Sawyer MG, Burns J, McMichael AJ. Declining blood lead levels and changes in cognitive function during childhood: the Port Pirie Cohort Study. JAMA 280: 1915-1919, 1998.
41. Wu YY, Bradshaw RA. Synergistic induction of neurite outgrowth by nerve growth factor or epidermal growth factor and interleukin-6 in PC12 cells. J Biol Chem 271: 13033-13039, 1996.